Related Experiment Videos
The titanium intraprostatic stent: the United States experience
S A Kaplan1, D C Merrill, W G Mosely
1Department of Urology, College of Physicians and Surgeons, Columbia University, New York, New York.
The Journal of Urology
|November 1, 1993
Summary
This study shows a titanium intraprostatic stent effectively treats urinary retention and benign prostatic hyperplasia symptoms. The stent improved voiding function and reduced symptoms in most patients, offering a viable alternative to surgery.
Area of Science:
- Urology
- Medical Devices
- Surgical Innovation
Background:
- Benign prostatic hyperplasia (BPH) causes lower urinary tract symptoms.
- High-risk patients often face limited treatment options beyond catheterization.
- Intraprostatic stents offer a minimally invasive approach to BPH management.
Purpose of the Study:
- To evaluate the initial United States experience with an expandable titanium intraprostatic stent.
- To assess the safety and efficacy of this novel stent in patients with BPH and urinary retention.
- To analyze changes in symptom scores, urine flow, and residual urine volume post-stent insertion.
Main Methods:
- A multicenter study involving 68 patients (aged 60-93) with BPH.
- Stent insertion under direct vision, expanded to 33F using a balloon catheter.
- Pre- and post-procedure evaluation of symptom scores, peak urine flow rate, and post-void residual urine volume.
Main Results:
- Symptom scores improved significantly, decreasing from 16.8 to 3.2 at 18 months.
- Peak urine flow rate increased from 3.9 ml/s to 14.4 ml/s at 18 months.
- 79% of patients with proper stent placement showed improved symptoms and flow; transient hematuria was common.
Conclusions:
- The titanium intraprostatic stent is a promising alternative for high-risk BPH patients.
- Proper placement is crucial for successful outcomes, avoiding technical failures.
- Further studies are needed to confirm long-term efficacy and durability.